119 related articles for article (PubMed ID: 37934043)
61. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
[TBL] [Abstract][Full Text] [Related]
62. Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.
Peinemann F; Harari M; Peternel S; Chan T; Chan D; Labeit AM; Gambichler T
Cochrane Database Syst Rev; 2020 May; 5(5):CD011941. PubMed ID: 32368795
[TBL] [Abstract][Full Text] [Related]
63. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England.
Khalid JM; Fox KM; Globe G; Maguire A; Chau D
J Dermatolog Treat; 2014 Feb; 25(1):67-72. PubMed ID: 23336246
[TBL] [Abstract][Full Text] [Related]
64. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
[TBL] [Abstract][Full Text] [Related]
65. Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK).
Myśliwiec H; Myśliwiec P; Baran A; Flisiak I
Adv Med Sci; 2016 Sep; 61(2):207-211. PubMed ID: 26895458
[TBL] [Abstract][Full Text] [Related]
66. Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
Acta Derm Venereol; 2021 Jan; 101(1):adv00357. PubMed ID: 33320277
[TBL] [Abstract][Full Text] [Related]
67. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
68. Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study.
Iskandar IYK; Lunt M; Thorneloe RJ; Cordingley L; Griffiths CEM; Ashcroft DM;
Br J Dermatol; 2021 Nov; 185(5):952-960. PubMed ID: 34128222
[TBL] [Abstract][Full Text] [Related]
69. C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B.
Farshchian M; Ansar A; Sobhan M; Hoseinpoor V
An Bras Dermatol; 2016; 91(5):580-583. PubMed ID: 27828628
[TBL] [Abstract][Full Text] [Related]
70. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
71. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.
Elnabawi YA; Dey AK; Goyal A; Groenendyk JW; Chung JH; Belur AD; Rodante J; Harrington CL; Teague HL; Baumer Y; Keel A; Playford MP; Sandfort V; Chen MY; Lockshin B; Gelfand JM; Bluemke DA; Mehta NN
Cardiovasc Res; 2019 Mar; 115(4):721-728. PubMed ID: 30721933
[TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
73. The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment.
Karpińska-Mirecka A; Bartosińska J; Krasowska D
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948777
[TBL] [Abstract][Full Text] [Related]
74. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis.
Carrascosa JM; Toro Montecinos M; Ballescá F; Teniente Serra A; Martínez Cáceres E; Ferrándiz C
J Dermatolog Treat; 2018 Mar; 29(2):140-144. PubMed ID: 28604127
[TBL] [Abstract][Full Text] [Related]
75. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.
Elberdín L; Outeda M; Salvador P; Paradela S; Fernández-Torres RM; Iglesias R; Fonseca E; Martín I
Int J Clin Pharm; 2016 Oct; 38(5):1142-8. PubMed ID: 27436193
[TBL] [Abstract][Full Text] [Related]
76. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
77. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
78. Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core: Results From a Prospective, Observational Study.
Choi H; Uceda DE; Dey AK; Abdelrahman KM; Aksentijevich M; Rodante JA; Elnabawi YA; Reddy A; Keel A; Erb-Alvarez J; Teague H; Playford MP; Zhou W; Chen MY; Gelfand JM; Bluemke DA; Buckler A; Mehta NN
Circ Cardiovasc Imaging; 2020 Sep; 13(9):e011199. PubMed ID: 32927971
[TBL] [Abstract][Full Text] [Related]
79. Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis.
Hjuler KF; Bøttcher M; Vestergaard C; Bøtker HE; Iversen L; Kragballe K
JAMA Dermatol; 2016 Oct; 152(10):1114-1121. PubMed ID: 27385305
[TBL] [Abstract][Full Text] [Related]
80. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
